Human RCTPubMed ID: 32107931·2020

STEP 2: Semaglutide for Weight Management with Comorbidities

Wadden TA, Bailey TS, Billings LK, et al.

Obesity, 2020 · n = 1210

Key finding

Semaglutide 2.4mg achieved 10.2% mean weight loss versus 3.2% placebo (p<0.001); 57% achieved ≥10% weight loss versus 16% with placebo.

Summary

Phase 3b trial of semaglutide 2.4mg in adults with obesity and comorbidities including diabetes and cardiovascular disease.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT